Longevity
A protein in muscle cells may help explain why exercise fights type 2 diabetes
By John Hyland, . Life and Health Today.
What the researchers found
A protein sitting on the outer surface of mitochondria, the structures inside cells that generate energy, may be a key reason skeletal muscle stops responding properly to insulin in type 2 diabetes. The protein is called Miro1, short for Mitochondrial Rho GTPase 1, and researchers found it present at higher levels in the muscle cells of people with the disease. The findings were published in Nature Communications.
The research team studied Miro1 across three settings: laboratory cells, preclinical models (meaning animals, not humans), and people living with type 2 diabetes. In the preclinical models, removing Miro1 restored the muscles' insulin response, according to Nature Communications. That is a meaningful result in animals, though it does not confirm the same mechanism operates identically in people.
The Nature Communications paper describes how insulin normally lowers Miro1 expression in skeletal muscle by triggering a chain of molecular events inside the cell. In people with type 2 diabetes, that process appears to break down, allowing Miro1 to accumulate and, the researchers argue, interfere with how muscle tissue handles blood sugar.
What the exercise trial showed
To test whether Miro1 levels could be changed in living people, the team ran a randomized controlled trial. According to PubMed, 24 patients with type 2 diabetes were assigned to either 12 weeks of aerobic exercise training or 12 weeks of standard medical care. Muscle Miro1 levels were measured at the start and again at the end.
Participants in the exercise group saw Miro1 levels fall in their muscles. Those reductions occurred alongside improvements in insulin sensitivity and in the muscles' capacity to produce energy, ScienceDaily Fitness reported. The standard-care group served as the comparison.
A trial of 24 people over 12 weeks can establish that a change happened; it is not large enough to confirm that lowering Miro1 is the mechanism responsible for the insulin improvements, or to rule out other effects of exercise. The study was designed to detect a signal, not to prove a treatment.
Why it matters and what remains open
Insulin resistance in skeletal muscle is central to type 2 diabetes: when muscle cells stop responding to insulin, the body cannot move glucose out of the bloodstream efficiently, and blood sugar climbs. The molecular reasons for that resistance have been difficult to pin down. Identifying Miro1 as a candidate gives researchers a specific target to investigate further.
ScienceDaily Fitness quoted the researchers as saying that "insulin resistance in muscle is at the heart of Type 2 diabetes, and its molecular causes have remained frustratingly unclear," describing Miro1 as "a key part of the answer."
The finding also offers a potential molecular explanation for something already known: that exercise improves insulin sensitivity. If aerobic activity lowers Miro1, and lower Miro1 is associated with better insulin response, that chain is worth following in larger trials.
No drug targeting Miro1 is currently available or approved. The preclinical removal experiments show what happens when the protein is eliminated in animal models; translating that into a safe, effective therapy in humans is a separate and much longer process. Whether Miro1 could eventually be targeted alongside exercise, or in people who cannot exercise, is an open question the current data cannot answer.
Source: https://www.sciencedaily.com/releases/2026/11/261106174543.htm
Life & Health Today provides information for educational purposes only, not medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional.